Program
BMB-101
A development code.
Its studies are mostly in Prader-Willi Syndrome · Epilepsy, Absence, led by Bright Minds Biosciences Pty.
Furthest: phase 2, since May 2, 20243 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bright Minds Biosciences Pty | 32 open or running | phase 2since May 2, 2024 | May 19, 2022 | Nov 2026phase 2 · NCT07266324 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2022First study: phase 1 study in HealthyFirst studyNCT05397041 · 81 enrolled · Australia
- May 2, 2024Phase 2 study in Epilepsy, AbsenceNCT06401538 · 20 planned · Australia
- Nov 17, 2025Phase 2 study in Prader-Willi SyndromeNCT07266324 · 16 planned · Australia
Ahead
- Nov 2026Primary completion: phase 2 study in Prader-Willi SyndromeNCT07266324
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07266324Prader-Willi Syndrome · Australia | 2 | Not yet recruiting | Nov 2026 | 16 |
| NCT06401538Epilepsy, Absence · Australia | 2 | Recruiting | Sep 15, 2025 | 20 |
| NCT05397041Healthy · Australia | 1 | Completed | May 4, 2023 | 81 |
How it is read
Names in the registry
- “BMB-101”, 3 entries
Codes read as this program: BMB101.
Conditions, from the studies’ own filings
- Prader-Willi Syndrome, 1 study
- Epilepsy, Absence, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.